What's Going On With Penny Stock AgeX Therapeutics?
What's Going On With Penny Stock AgeX Therapeutics?
Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc (NYSE:PFE) will license, on a non-exclusive basis, Serina's POZ polymer technology.
Serina Therapeutics Inc是一家处于临床阶段的私营生物技术公司，它签订了一项许可协议，根据该协议，辉瑞公司（纽约证券交易所代码：PFE）将在非排他性的基础上许可Serina的POZ聚合物技术。
Serina is focused on developing its proprietary POZ Platform drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics.
Serina专注于开发其专有的POZ平台药物递送技术，包括用于基于RNA的疗法的POZ脂质纳米颗粒（LNP）递送系统。
"We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities," stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. "The license agreement represents an important milestone for Serina."
Serina Therapeutics执行董事会主席米尔顿·哈里斯博士说：“我们很高兴辉瑞获准在初始研发活动中使用POZ聚合物技术。”“许可协议对Serina来说是一个重要的里程碑。”
In August, Serina Therapeutics announced a merger agreement with AgeX Therapeutics Inc (NYSE:AGE) in an all-stock transaction.
8月，Serina Therapeutics宣布与Agex Therapeutics Inc（纽约证券交易所代码：AGE）签订全股交易合并协议。
The combined company will continue under the Serina Therapeutics name and will focus on advancing the pipeline of small molecule drug candidates targeting central nervous system indications, enabled by the company's proprietary POZ Platform delivery technology.
合并后的公司将继续使用Serina Therapeutics的名义，并将在公司专有的POZ Platform交付技术支持下，专注于推进靶向中枢神经系统适应症的小分子候选药物的产品线。
According to data from Benzinga Pro, AgeX Therapeutics stock is trading lower on heavy volume, with a session volume of 9.9 million shares traded, compared to the trailing 100-day volume of 17.29k shares.
根据Benzinga Pro的数据，由于交易量大，Agex Therapeutics的股票交易量走低，交易量为990万股，而过去100天的交易量为17.29万股。
Price Action: AGE shares are down 28.3% at $0.42 on the last check Friday.
价格走势：周五上一次支票时，AGE股价下跌28.3％，至0.42美元。